Reference Citation Analysis: Find an Article, Find a Category, Find a Journal, Find a Scholar

Citation(s) in RCA

1
(from Reference Citation Analysis)

Indexed Articles

Ranked By

Results Analysis

Year Published Analysis
Article Type Analysis
Journal Title Analysis
Category Analysis

Results Analysis

Year Published

Show more Refine

Article Statistics

Refine

Publication Titles

Show more Refine

Category

Show more Refine

For: Eliasof S, Conley S, Keefe SM, Kerbel R, Krasner CN, Lazarus D, Peters C, Pham E, Wicha MS, Garmey EG. Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-pr09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

For:	Eliasof S, Conley S, Keefe SM, Kerbel R, Krasner CN, Lazarus D, Peters C, Pham E, Wicha MS, Garmey EG. Abstract PR09: Synergistic activity of CRLX101, a nanopharmaceutical in Phase II clinical trials, with antiangiogenic therapies mediated through HIF-1alpha inhibition: A translational research program. Mol Cancer Ther 2013. [DOI: 10.1158/1535-7163.targ-13-pr09] [Citation(s) in RCA: 1] [Impact Index Per Article: 0.1] [Reference Citation Analysis] [What about the content of this article? (0)] [Track Full Text] [Journal Information] [Subscribe] [Scholar Register] [Indexed: 11/16/2022]

Number

Cited by Other Article(s)

Luu DC, Chao J. How can we manage resistance to antiangiogenic drugs? CLINICAL INVESTIGATION 2014;4:483-486. [PMID: 25520773 PMCID: PMC4266529 DOI: 10.4155/cli.14.46] [Citation(s) in RCA: 0] [Impact Index Per Article: 0] [Reference Citation Analysis] [Key Words] [Grants] [Track Full Text] [Subscribe] [Scholar Register] [Indexed: 06/04/2023]